Agreement will deliver novel handheld analyzers for the point-of-care hemostasis testing market
Siemens Healthcare Diagnostics and Universal Biosensors (Melbourne, Australia) have signed a strategic partnership agreement to launch a new point-of-care (POC) coagulation testing platform for the global hemostasis market. This agreement harnesses Universal Biosensors’ opposing electrode technology as well as Siemens’ strong market positions in both the central laboratory and POC settings, along with its innovative know-how in creating advanced hemostasis testing solutions. Together, the companies will develop, manufacture and distribute a series of novel handheld POC coagulation testing systems providing unique value and quality to healthcare professionals.
Leveraging a growing demand for near-patient testing solutions, including those that deliver time-critical coagulation data, Siemens and Universal Biosensors will focus on offering new technologies that deliver laboratory-quality results at the point of care. The first solution scheduled for release is a prothrombin time (PT) test. Additional products with enhanced menus and extended capabilities are anticipated over time.
“Siemens recognizes the growth in demand for laboratory-quality tests that can be conducted near
patients to produce reliable, immediate results,” said David Stein, Ph.D., CEO, Point of Care
Business Unit at Siemens Healthcare Diagnostics. “As a hemostasis market leader, we’re excited
about our new partnership with Universal Biosensors to help further extend our broad POC testing
position and to ensure the delivery of innovative new solutions that enable physicians to make
faster, more informed decisions for improved patient care.”
“We are delighted to establish this relationship with Siemens Healthcare Diagnostics,” said Paul
Wright, CEO of Universal Biosensors. “In partnership, we are well placed to provide highly
accurate, cost-effective solutions for the POC market, and we look forward to a long-term collaborative relationship with Siemens.”